Mn(II) Quinoline Complex (4QMn) Restores Proteostasis and Reduces Toxicity in Experimental Models of Huntington's Disease

Fecha de publicación: 01/08/2022 Fecha Ahead of Print: 11/08/2022

Autores de IIS La Fe

• Mariam Merino Gamiz

  Autor

• Ana Virginia Sanchez Sanchez

  Autor

• Rafael Vázquez Manrique

  Autor

Participantes ajenos a IIS La Fe

• Sequedo, Maria Dolores
• Clares, Ma Paz
• Garcia-Espana, Enrique
• Mullor, Jose L.

Grupos

• Biomedicina Molecular, Celular y Genómica

  

  Leader

  José María Millán Salvador

• Unidad mixta de investigación en enfermedades raras (CIPF)

  

  Leader

  José María Millán Salvador

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, of the so-called minority diseases, due to its low prevalence. It is caused by an abnormally long track of glutamines (polyQs) in mutant huntingtin (mHtt), which makes the protein toxic and prone to aggregation. Many pathways of clearance of badly-folded proteins are disrupted in neurons of patients with HD. In this work, we show that one Mn(II) quinone complex (4QMn), designed to work as an artificial superoxide dismutase, is able to activate both the ubiquitin-proteasome system and the autophagy pathway in vitro and in vivo models of HD. Activation of these pathways degrades mHtt and other protein-containing polyQs, which restores proteostasis in these models. Hence, we propose 4QMn as a potential drug to develop a therapy to treat HD.

Keywords

• Mn(II) complexes; Huntington's disease; polyQ toxicity; autophagy; proteasome; Caenorhabditis elegans